• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

biopharma

  1. Any salesforce layoffs due to Covid-19 yet

    Obviously this is unprecedented times right now. I am curious if any companies have begun sales force layoffs and if so were they furloughed or just straight laid off? Hoping to weather the storm at our company, but it’s still so fluid
  2. Novo Nordisk reports first quarter results

    Novo Nordisk says pricing pressure within diabetes to continue, especially in the US. First quarter 2019 results: Sales from North America Operations declined 4% on constant exchange rates.
  3. Alzheimer’s disease trial - Axsome Therapeutics reports positive outcome

    Axsome Therapeutics stock skyrockets on positive outcome from Alzheimer's disease trial https://news.alphastreet.com/axsome-therapeutics-nasdaq-axsm-stock-almost-doubles-on-positive-outcome-from-alzheimers-disease-trial-in-premarket/
  4. Bristol-Myers Squibb swallows Celgene for $74 billion

    Bristol-Myers Squibb acquires Celgene for $74 billion. Celgene stock surges while BMY plunges. 2019 starts well for Celgene. More M&As are in the pipeline in the biopharma space.
  5. Celgene/BeiGene collaboration

    Is this deal advantageous for Celgene? BeiGene (ADR) has surged nearly 28% as of now.